Cempra's pivotal phase 3 SOLITAIRE-IV study of IV to oral solithromycin published
Cempra announced the publication of its pivotal Phase 3 study, SOLITAIRE-IV, comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in Clinical Infectious Diseases. August 25, 2016